Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Crispr Therapeutics AG(CRSP)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CRSP
09/25/2026: CRSP (1-star) is currently NOT-A-BUY. Pass it for now.
CRISPR Therapeutics is a pioneering biotechnology company known for developing gene-edited medicines using its proprietary CRISPR/Cas9 platform. Its most notable milestone is the recent regulatory approval of CASGEVY, a therapy for serious blood disorders developed with Vertex Pharmaceuticals. This success gives the company a strong foothold in the emerging genomic medicine market, though its business remains in the early stages of commercial growth. Investors face risks related to high operational costs, complex product delivery, and potential competition from other gene-editing technologies. The stock is best suited for growth-oriented investors with a long-term horizon who are prepared for the volatility associated with clinical-stage biotechnology.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high-growth potential driven by its pioneering role in the gene-editing market. |
| Momentum investor | Mixed fit | Momentum is highly dependent on news cycles regarding clinical trials and regulatory decisions. |
| Value investor | Weak fit | The stock trades based on long-term growth prospects rather than current earnings or book value. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses all capital on growth. |
| Low-risk investor | Weak fit | The company is subject to high volatility typical of clinical-stage biotech stocks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stock prices are sensitive to clinical and regulatory outcomes. |
| Valuation risk | Medium / high | Market expectations for long-term growth often lead to high valuation multiples. |
| Competition risk (gene editing) | Medium | Other firms are developing novel gene editing tools that could displace existing technologies. |
| Business quality | Medium | While the platform is revolutionary, the business is still in early commercial stages. |
| Dividend income | Low / none | Investors should not expect income from this stock. |
| Execution risk | High | Scaling commercial delivery and manufacturing of personalized therapies is complex. |
Price Behavior
Flat / Range-Bound
The stock price has been trading within a narrow range with minimal directional movement.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -50.45% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.24B USD | Price to earnings Ratio - | 1Y Target Price 87.56 |
Price to earnings Ratio - | 1Y Target Price 87.56 | ||
Volume (30-day avg) 1.7M shares | Beta 1.76 | 52 Weeks Range 44.12 - 78.48 | Updated Date 09/27/2026 |
52 Weeks Range 44.12 - 78.48 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.71 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Collaboration and Licensing | Milestone payments and royalties from partnerships like Vertex Pharmaceuticals. | Revenue is largely tied to meeting specific development milestones under partner agreements. |
| Product Commercialization | Revenue generated from the sale of approved therapies like CASGEVY. | The company is beginning to transition toward direct product sales revenue. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 23.36 | Enterprise Value 3.81B | Price to Sales(TTM) 391.55 |
Enterprise Value 3.81B | Price to Sales(TTM) 391.55 | ||
Enterprise Value to Revenue 346.45 | Enterprise Value to EBITDA 14.16 | Shares Outstanding 96.69M | Shares Floating 96.26M |
Shares Outstanding 96.69M | Shares Floating 96.26M | ||
Percent Insiders 5.89 | Percent Institutions 77.68 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Crispr Therapeutics AG
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2016-10-19 | CEO & Chairman Dr. Samarth Kulkarni Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 393 | Website https://www.crisprtx.com |
Full time employees 393 | Website https://www.crisprtx.com | ||
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.